Regeneron Pharmaceuticals Inc REGN:NASDAQ

Last Price$296.85NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/16/19

Today's Change+3.74(1.28%)
Bid (Size)$290.01 (2)
Ask (Size)$296.87 (1)
Day Low / High$290.72 - 297.35
Volume742.6 K

View Biotechnology IndustryPeer Comparison as of 08/16/2019


Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $296.85
Change: +3.74 (1.28%)
Volume: 742.6 K
4:00PM ET 8/16/2019

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $110.85
Change: +1.81 (1.66%)
Volume: 1.3 M
3:59PM ET 8/16/2019

Agilent Technologies Inc ( NYSE )

Price: $71.08
Change: +1.49 (2.14%)
Volume: 3.4 M
4:02PM ET 8/16/2019

Illumina Inc ( NASDAQ )

Price: $286.17
Change: +1.40 (0.49%)
Volume: 926.7 K
4:00PM ET 8/16/2019

Biogen Inc ( NASDAQ )

Price: $231.68
Change: +4.05 (1.78%)
Volume: 1.1 M
3:59PM ET 8/16/2019

Read more news Recent News

Regeneron Pharmaceuticals Says Trial Shows Efficacy in Genetic Cholesterol Disorder Treatment
11:47AM ET 8/14/2019 MT Newswires

Regeneron Pharmaceuticals (REGN) said it achieved positive phase 3 trial results for evinacumab, a monoclonal antibody that specifically binds to...

Regeneron Pharma's EYLEA Injection Prefilled Syringe Gets Regulator Nod - Stock Up 3%
2:32PM ET 8/13/2019 MT Newswires

Regeneron Pharmaceuticals (REGN) said on Tuesday the US Food and Drug Administration has approved the Chemistry, Manufacturing and Controls Prior-Approval...

Regeneron Says REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
3:15PM ET 8/12/2019 MT Newswires

Regeneron Pharmaceuticals (REGN), a clinical stage biopharmaceutical company, said on Monday that a clinical trial evaluating four investigational...

Analysts' Scale Up Regeneron Pharmaceuticals' Q3, 2019, 2020 Earnings Estimates
8:01AM ET 8/09/2019 MT Newswires

Q3, 2019, and 2020`s earnings forecasts for Regeneron Pharmaceuticals Inc (NASDAQ:REGN, Recent Price: 309.87) have been scaled up. The Q3 earnings estimate...

Company Profile

Business DescriptionRegeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. View company web site for more details
Address777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
Number of Employees7,400
Recent SEC Filing08/06/20198-K
Co-President, Chief Executive Officer & DirectorLeonard S. Schleifer
Co-President, Director & Chief Scientific OfficerGeorge Damis Yancopoulos
Chief Financial Officer & Executive VP-FinanceRobert E. Landry
Chief Compliance Officer & Senior Vice PresidentBeth F. Levine

Company Highlights

Price Open$295.32
Previous Close$293.11
52 Week Range$287.66 - 442.00
Market Capitalization$32.1 B
Shares Outstanding108.0 M
SectorHealth Technology
Next Earnings Announcement11/05/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings14.05
Earnings per Share$18.80
Beta vs. S&P 500N/A
Revenue$6.7 B
Net Profit Margin29.94%
Return on Equity24.89%

Analyst Ratings as of 08/09/2019

Consensus RecommendationConsensus Icon
Powered by Factset